Indications and Purposes
| 1 Indications And Usage Vyxeos Is Indicated For The Treatment Of Adults With Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (T-Aml) Or Aml With Myelodysplasia-Related Changes (Aml-Mrc). Vyxeos Is A Liposomal Combination Of Daunorubicin, An Anthracycline Topoisomerase Inhibitor, And Cytarabine, A Nucleoside Metabolic Inhibitor, That Is Indicated For The Treatment Of Adults With Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (T-Aml) Or Aml With Myelodysplasia-Related Changes (Aml-Mrc). ( 1 ) |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 2 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Cytarabine |
|
ZINC3795098 |
| 2. Daunorubicin |
|
ZINC3917708 |